首页> 外文期刊>Medical Physics >Statistical process control for IMRT dosimetric verification.
【24h】

Statistical process control for IMRT dosimetric verification.

机译:用于IMRT剂量验证的统计过程控制。

获取原文
获取原文并翻译 | 示例
           

摘要

Patient-specific measurements are typically used to validate the dosimetry of intensity-modulated radiotherapy (IMRT). To evaluate the dosimetric performance over time of our IMRT process, we have used statistical process control (SPC) concepts to analyze the measurements from 330 head and neck (H&N) treatment plans. The objectives of the present work are to: (i) Review the dosimetric measurements of a large series of consecutive head and neck treatment plans to better understand appropriate dosimetric tolerances; (ii) analyze the results with SPC to develop action levels for measured discrepancies; (iii) develop estimates for the number of measurements that are required to describe IMRT dosimetry in the clinical setting; and (iv) evaluate with SPC a new beam model in our planning system. H&N IMRT cases were planned with the PINNACLE treatment planning system versions 6.2b or 7.6c (Philips Medical Systems, Madison, WI) and treated on Varian (Palo Alto, CA) or Elekta (Crawley, UK) linacs. As part of regular quality assurance, plans were recalculated on a 20-cm-diam cylindrical phantom, and ion chamber measurements were made in high-dose volumes (the PTV with highest dose) and in low-dose volumes (spinal cord organ-at-risk, OR). Differences between the planned and measured doses were recorded as a percentage of the planned dose. Differences were stable over time. Measurements with PINNACLE3 6.2b and Varian linacs showed a mean difference of 0.6% for PTVs (n=149, range, -4.3% to 6.6%), while OR measurements showed a larger systematic discrepancy (mean 4.5%, range -4.5% to 16.3%) that was due to well-known limitations of the MLC model in the earlier version of the planning system. Measurements with PINNACLE3 7.6c and Varian linacs demonstrated a mean difference of 0.2% for PTVs (n=160, range, -3.0%, to 5.0%) and -1.0% for ORs (range -5.8% to 4.4%). The capability index (ratio of specification range to range of the data) was 1.3 for the PTV data, indicating that almost all measurements were within +/-5%. We have used SPC tools to evaluate a new beam model in our planning system to produce a systematic difference of -0.6% for PTVs and 0.4% for ORs, although the number of measurements is smaller (n=25). Analysis of this large series of H&N IMRT measurements demonstrated that our IMRT dosimetry was stable over time and within accepted tolerances. These data provide useful information for assessing alterations to beam models in the planning system. IMRT is enhanced by the addition of statistical process control to traditional quality control procedures.
机译:特定于患者的测量通常用于验证强度调制放射疗法(IMRT)的剂量。为了评估IMRT过程随时间的剂量学性能,我们使用了统计过程控制(SPC)概念来分析330种头颈(H&N)治疗计划的测量结果。当前工作的目的是:(i)审查一系列连续的头颈治疗计划的剂量学测量,以更好地了解适当的剂量学公差; (ii)与SPC分析结果,以制定可衡量差异的行动水平; (iii)对描述IMRT剂量测定法在临床环境中所需的测量次数进行估算; (iv)在我们的计划系统中使用SPC评估新的梁模型。 H&N IMRT病例使用PINNACLE治疗计划系统版本6.2b或7.6c(Philips Medical Systems,Madison,WI)进行计划,并在Varian(Palo Alto,CA)或Elekta(Crawley,UK)直线加速器上进行治疗。作为常规质量保证的一部分,计划在直径20厘米的圆柱体模上重新计算计划,并在高剂量体积(最大剂量的PTV)和低剂量体积(脊髓器官正常)中进行离子室测量-风险)。计划剂量和测量剂量之间的差异记录为计划剂量的百分比。随着时间的推移,差异是稳定的。用PINNACLE3 6.2b和瓦里纳直线加速器进行的测量显示,PTV的平均差异为0.6%(n = 149,范围为-4.3%至6.6%),而OR测量结果则显示出较大的系统差异(平均值为4.5%,范围为-4.5%至16.3%)是由于较早版本的计划系统中的MLC模型存在众所周知的局限性。用PINNACLE3 7.6c和瓦里纳直线加速器进行的测量显示,PTV的平均差异为0.2%(n = 160,范围为-3.0%至5.0%),OR的平均差异为-1.0%(范围为-5.8%至4.4%)。 PTV数据的能力指数(规格范围与数据范围之比)为1.3,表明几乎所有测量值均在+/- 5%之内。尽管测量数量较小(n = 25),但我们已使用SPC工具在规划系统中评估新的光束模型,以使PTV产生-0.6%的系统差异,OR产生0.4%的系统差异。对H&N IMRT这一大系列测量结果的分析表明,我们的IMRT剂量测定随时间推移且在可接受的公差内是稳定的。这些数据为评估规划系统中梁模型的更改提供了有用的信息。通过向传统质量控制程序中添加统计过程控制来增强IMRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号